Bristol-Myers Squibb Company (BMY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bristol-Myers Squibb Company (BMY) trades at $59.60 with AI Score 55/100 (Hold). Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. Market cap: $121.37B, Sector: Healthcare.
Last analyzed: Feb 9, 2026Bristol-Myers Squibb Company (BMY) Healthcare & Pipeline Overview
Bristol-Myers Squibb pioneers innovative biopharmaceutical solutions, leveraging a diverse portfolio of oncology, hematology, and immunology drugs, including Eliquis and Opdivo, to address unmet medical needs and deliver strong shareholder value with a 4.02% dividend yield and a 14.6% profit margin.
Investment Thesis
Bristol-Myers Squibb presents a notable research candidate driven by its diverse portfolio of established and innovative biopharmaceutical products. With a market capitalization of $126.20 billion and a P/E ratio of 17.89, BMY offers a blend of value and growth potential. The company's strong profit margin of 14.6% and gross margin of 63.1% demonstrate its ability to generate significant earnings. Key growth catalysts include the continued expansion of Opdivo and Eliquis, as well as the successful launch of new products like Zeposia and Breyanzi. BMY's commitment to research and development, coupled with strategic acquisitions and partnerships, positions it for long-term growth and value creation. The company's attractive dividend yield of 4.02% provides investors with a steady stream of income while benefiting from potential capital appreciation.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $126.20 billion reflects BMY's significant presence in the biopharmaceutical industry.
- P/E ratio of 17.89 indicates a reasonable valuation relative to earnings.
- Profit margin of 14.6% demonstrates strong profitability and operational efficiency.
- Gross margin of 63.1% highlights BMY's ability to maintain competitive pricing and manage costs effectively.
- Dividend yield of 4.02% provides an attractive income stream for investors.
Competitors & Peers
Strengths
- Diverse portfolio of established and innovative products.
- Strong research and development capabilities.
- Global presence and distribution network.
- Experienced management team.
Weaknesses
- Reliance on key products with patent expirations.
- Exposure to generic competition.
- High research and development costs.
- Regulatory and legal risks.
Catalysts
- Clinical trial results for new drug candidates in oncology and immunology.
- Expansion of Opdivo into new indications and combination therapies.
- Successful launch and market penetration of Zeposia and Breyanzi.
- Strategic acquisitions and partnerships to expand the pipeline.
Risks
- Patent expirations on key products leading to generic competition.
- Unfavorable clinical trial results impacting drug development.
- Regulatory and legal challenges related to drug pricing and marketing.
- Competition from other pharmaceutical companies and biosimilar manufacturers.
Growth Opportunities
- Expansion of Opdivo into new indications: Opdivo, BMY's leading anti-cancer therapy, has the potential for further growth through expansion into new indications and combination therapies. The global oncology market is projected to reach $350 billion by 2030, providing a significant opportunity for BMY to increase Opdivo's market share and drive revenue growth. This expansion is ongoing as of 2026-02-09.
- Growth of Eliquis in the cardiovascular market: Eliquis, an oral inhibitor for stroke prevention and treatment of DVT/PE, continues to experience strong growth in the cardiovascular market. With the increasing prevalence of atrial fibrillation and venous thromboembolism, Eliquis is well-positioned to capture a larger share of the market, which is expected to reach $30 billion by 2028. This growth is ongoing as of 2026-02-09.
- Successful launch of new products: BMY's recent launches of Zeposia for multiple sclerosis and Breyanzi for lymphoma represent significant growth opportunities. These innovative therapies address unmet medical needs and have the potential to generate substantial revenue. The market for multiple sclerosis therapies is expected to reach $25 billion by 2027, while the market for lymphoma therapies is projected to reach $20 billion by 2028. This launch is ongoing as of 2026-02-09.
- Strategic acquisitions and partnerships: BMY has a history of strategic acquisitions and partnerships to expand its pipeline and strengthen its market position. These collaborations provide access to new technologies, therapeutic areas, and markets, driving long-term growth and innovation. BMY will continue to explore strategic opportunities to enhance its portfolio and create value for shareholders. This strategy is ongoing as of 2026-02-09.
- Emerging Markets Expansion: Expanding into emerging markets presents a significant growth opportunity for BMY. These markets, characterized by rapidly growing populations and increasing healthcare spending, offer substantial potential for increased sales and market share. BMY can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets and drive revenue growth. This expansion is ongoing as of 2026-02-09.
Opportunities
- Expansion into new therapeutic areas.
- Strategic acquisitions and partnerships.
- Growth in emerging markets.
- Development of personalized medicine.
Threats
- Increasing competition from generic and biosimilar drugs.
- Pricing pressures and healthcare reforms.
- Unfavorable clinical trial results.
- Product liability claims.
Competitive Advantages
- Strong intellectual property protection through patents and exclusivity.
- Established brand reputation and trust among healthcare professionals.
- Extensive research and development capabilities.
- Global distribution network and market access.
About BMY
Founded in 1887, Bristol-Myers Squibb (BMY) has evolved into a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. Originally known as Bristol-Myers Company, the company has a rich history of scientific innovation and a commitment to addressing unmet medical needs. BMY's diverse portfolio includes market-leading products across several therapeutic areas, including oncology, hematology, immunology, cardiovascular, and fibrotic diseases. Key products include Revlimid, an oral immunomodulatory drug for multiple myeloma; Eliquis, an oral inhibitor for stroke prevention and treatment of DVT/PE; and Opdivo, an anti-cancer therapy for various indications. Other notable products include Pomalyst/Imnovid, Orencia, Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Breyanzi, Inrebic, and Onureg. BMY markets its products globally through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies, maintaining a strong presence in key markets worldwide. With a workforce of 34,100 employees, BMY continues to invest in research and development to drive future growth and deliver innovative therapies to patients in need.
What They Do
- Discovers and develops innovative biopharmaceutical products.
- Licenses and manufactures pharmaceutical products.
- Markets and sells biopharmaceutical products globally.
- Offers therapies for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases.
- Provides treatments for multiple myeloma, stroke prevention, and various cancers.
- Sells products to wholesalers, distributors, pharmacies, hospitals, and government agencies.
Business Model
- Develops and patents innovative pharmaceutical products.
- Manufactures and distributes drugs through various channels.
- Generates revenue through the sale of prescription medications.
- Invests heavily in research and development to discover new therapies.
Industry Context
Bristol-Myers Squibb operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The global pharmaceutical market is expected to continue growing, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. BMY competes with other major pharmaceutical companies, such as GSK, CI, CVS, and ELV, for market share and innovation leadership. The company's success depends on its ability to develop and commercialize innovative therapies, navigate regulatory hurdles, and maintain a strong competitive position in key therapeutic areas.
Key Customers
- Wholesalers and distributors of pharmaceutical products.
- Pharmacies and retailers that dispense medications.
- Hospitals and clinics that administer treatments.
- Government agencies and healthcare providers.
Financials
Chart & Info
Bristol-Myers Squibb Company (BMY) stock price: $59.60 (+0.00, +0.00%)
Latest News
-
Colgate-Palmolive Boosts Payout, Adds New Director to Board
Yahoo! Finance: BMY News · Mar 26, 2026
-
Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank
defenseworld.net · Mar 26, 2026
-
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
Yahoo! Finance: BMY News · Mar 25, 2026
-
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
zacks.com · Mar 25, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMY.
Price Targets
Consensus target: $63.91
MoonshotScore
What does this score mean?
The MoonshotScore rates BMY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Colgate-Palmolive Boosts Payout, Adds New Director to Board
Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Latest Bristol-Myers Squibb Company Analysis
Common Questions About BMY (Healthcare)
What does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. The company's diverse portfolio includes market-leading products across several therapeutic areas, including oncology, hematology, immunology, cardiovascular, and fibrotic diseases. BMY markets its products globally through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company invests heavily in research and development to drive future growth and deliver innovative therapies to patients in need, with a commitment to addressing unmet medical needs and transforming patients' lives through science.
Is BMY stock worth researching?
BMY stock presents a mixed outlook. The company's strong dividend yield of 4.02% and established product portfolio offer stability. However, investors may want to evaluate the risks associated with patent expirations and generic competition. The successful launch of new products like Zeposia and Breyanzi, along with potential expansion of Opdivo, could drive future growth. A thorough analysis of BMY's pipeline, financial performance, and industry trends is essential before making an investment decision. With a P/E ratio of 17.89, BMY appears reasonably valued, but future growth is crucial to justify the investment.
What are the main risks for BMY?
BMY faces several key risks, including patent expirations on key products, which could lead to generic competition and reduced revenue. Unfavorable clinical trial results could impact the development of new drugs and delay product launches. Regulatory and legal challenges related to drug pricing and marketing practices could also pose risks. Additionally, BMY faces competition from other pharmaceutical companies and biosimilar manufacturers, which could erode market share and profitability. These risks require careful monitoring and mitigation strategies to ensure the company's long-term success.
What are the key factors to evaluate for BMY?
Bristol-Myers Squibb Company (BMY) currently holds an AI score of 55/100, indicating moderate score. Analysts target $63.91 (+7% from $59.60). Key strength: Diverse portfolio of established and innovative products. Primary risk to monitor: Patent expirations on key products leading to generic competition. This is not financial advice.
How frequently does BMY data refresh on this page?
BMY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BMY's recent stock price performance?
Recent price movement in Bristol-Myers Squibb Company (BMY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $63.91 implies 7% upside from here. Notable catalyst: Diverse portfolio of established and innovative products. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BMY overvalued or undervalued right now?
Determining whether Bristol-Myers Squibb Company (BMY) is overvalued or undervalued requires examining multiple metrics. Analysts target $63.91 (+7% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BMY?
Before investing in Bristol-Myers Squibb Company (BMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update. Financial metrics based on available information as of 2026-02-09.